Millendo Therapeutics Receives $62,000,000 Series B Funding
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6794ee49-4c1d-40fe-898b-b602349ea9ff
Date 1/4/2016
Company Name Millendo Therapeutics
Mailing Address 301 N. Main St. Ann Arbor, MI 48104 USA
Company Description Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. Our product candidates seek to improve the quality of life for patients with orphan and specialty diseases with limited or no approved treatment options.
Proceeds Purposes This acquisition of MLE4901 combined with the new funding and our current programs around ATR-101 puts us on a new trajectory to build a specialty pharmaceutical company focused on multiple disease-modifying treatments for endocrine disorders caused by hormone dysregulation.